论文部分内容阅读
白介素-2(interleukin-2,IL-2)是最早发现并应用于临床的细胞因子之一。最初IL-2因具有刺激T细胞增殖的能力引人关注,随后更多研究发现IL-2主要通过结合IL-2受体(interleukin-2 recepter,IL-2R)激活下游信号通路改变调节性T细胞(regulatory T cells,Tregs)与效应性T细胞(effector T cells,Teffs)间的比例,维持免疫耐受,实现人为调节免疫介导疾病的过程。近年来,IL-2在自身免疫性疾病、肿瘤免疫及器官移植耐受诱导中具有广泛的应用前景而备受瞩目。本文主要对IL-2和IL-2受体、其信号传导通路及免疫治疗作用做一综述。
Interleukin-2 (IL-2) is one of the earliest and clinical cytokines. Initially, IL-2 has drawn attention due to its ability to stimulate T cell proliferation. More studies have subsequently found that IL-2 activates downstream signaling pathway mainly through the binding of interleukin-2 receptor (IL-2R) The ratio between regulatory T cells (Tregs) and effector T cells (Teffs) maintains the immune tolerance and realizes the process of artificially regulating immune-mediated diseases. In recent years, IL-2 has attracted a great deal of attention in the fields of autoimmune diseases, tumor immunity and organ transplantation tolerance induction. This article mainly reviews IL-2 and IL-2 receptors, their signal transduction pathways and immunotherapeutic effects.